Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AusperBio raises $120m to progress hepatitis B therapies
The funds will advance AHB-137, an antisense oligonucleotide therapy for chronic hepatitis B, towards Phase III and commercial readiness. Credit: Jo Panuwat D / Shutterstock.com.
The funds will advance AHB-137, an antisense oligonucleotide therapy for chronic hepatitis B, towards Phase III and commercial readiness. Credit: Jo Panuwat D / Shutterstock.com.